Y-Intercept (HK)’s Akero Therapeutics AKRO Stock Holding History

Y-Intercept (HK)’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,661	Closed	-$364K	–	1498
2025 Q3	$364K	Sell	7,661 -31,341	-80%	-$1.52M	0.01%	1331
2025 Q2	$2.08M	Buy	+39,002	New	+$1.77M	0.05%	586
2025 Q1	–	Sell	-8,950	Closed	-$249K	–	1158
2024 Q4	$249K	Sell	8,950 -7,966	-47%	-$241K	0.02%	991
2024 Q3	$485K	Buy	16,916 +2,049	+14%	+$53.4K	0.03%	789
2024 Q2	$349K	Buy	14,867 +1,483	+11%	+$31.7K	0.02%	974
2024 Q1	$338K	Buy	+13,384	New	+$321K	0.03%	904

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Y-Intercept (HK)'s AKRO Position: Q4 2025 in Review

Y-Intercept (HK) sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 7,661 shares — an estimated $364K sold.

Y-Intercept (HK) first reported a position in AKRO in Q1 2024 and held it in 6 quarters. The position peaked at $2.08M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Y-Intercept (HK) reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Y-Intercept (HK) sold 7,661 Akero Therapeutics shares in Q4 2025, an estimated $364K.
Y-Intercept (HK) first reported a position in Akero Therapeutics in Q1 2024 and held it in 6 quarters.
Y-Intercept (HK)'s Akero Therapeutics position peaked at $2.08M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Y-Intercept (HK)'s 13F filing for Q4 2025, filed 13 Feb 2026.